These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 21547915

  • 1. Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors.
    Sjo OH, Berg M, Merok MA, Kolberg M, Svindland A, Lothe RA, Nesbakken A.
    J Surg Oncol; 2011 Dec; 104(7):792-7. PubMed ID: 21547915
    [Abstract] [Full Text] [Related]

  • 2. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT.
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Peritoneal carcinomatosis in patients with digestive endocrine tumors.
    Vasseur B, Cadiot G, Zins M, Fléjou JF, Belghiti J, Marmuse JP, Vilgrain V, Bernades P, Mignon M, Ruszniewski P.
    Cancer; 1996 Oct 15; 78(8):1686-92. PubMed ID: 8859181
    [Abstract] [Full Text] [Related]

  • 5. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.
    J Clin Oncol; 2005 Aug 20; 23(24):5635-43. PubMed ID: 16110022
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CIMP status of interval colon cancers: another piece to the puzzle.
    Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH, Shaukat A.
    Am J Gastroenterol; 2010 May 20; 105(5):1189-95. PubMed ID: 20010923
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peritoneal involvement in stage II colon cancer.
    Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K.
    Am J Clin Pathol; 2003 Jan 20; 119(1):108-13. PubMed ID: 12520705
    [Abstract] [Full Text] [Related]

  • 11. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, Slooff MJ, van Goor H, van den Berg A.
    Clin Cancer Res; 2005 Jun 01; 11(11):4067-73. PubMed ID: 15930341
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Colorectal carcinoma: correlation between age, gender and subsite distribution.
    Efremidou EI, Liratzopoulos N, Papageorgiou SM, Romanidis K, Tourlis T, Kouklakis G, Manolas KJ.
    Chirurgia (Bucur); 2008 Jun 01; 103(6):659-63. PubMed ID: 19274910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms of oncogenesis in colon versus rectal cancer.
    Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH.
    J Pathol; 2001 Sep 01; 195(2):171-8. PubMed ID: 11592095
    [Abstract] [Full Text] [Related]

  • 17. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.
    Cancer Res; 2001 Mar 15; 61(6):2505-12. PubMed ID: 11289122
    [Abstract] [Full Text] [Related]

  • 20. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, TP53-CRC Collaborative Study Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7518-28. PubMed ID: 16172461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.